Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
- PMID: 17196944
- DOI: 10.1016/j.brainres.2006.12.011
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
Abstract
We tested the ability of simvastatin, atorvastatin, fenofibrate and bezafibrate (two synthetic peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonists) to prevent dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Tyrosine hydroxylase (TH) immunochemistry was performed 8 days after acute MPTP intoxication. When orally administered for the week prior to intoxication and a week thereafter, fenofibrate prevented the MPTP-induced dopaminergic cell loss in the substantia nigra pars compacta (SNpc) and attenuated the loss of tyrosine hydroxylase immunoreactivity in the striatum. The dosage of 1-methyl-4-phenyl pyridinium (MPP+) in the striatum by high-performance liquid chromatography indicated that fenofibrate did not affect MPTP metabolism. Bezafibrate had no effect and, strikingly, simvastatin and atorvastatin had a negative effect. We also demonstrated the presence of PPAR-alpha in the dopaminergic neurons of the murine substantia nigra. Our data suggest that PPAR-alpha activation by fenofibrate could have a neuroprotective effect in PD through inhibition of inflammation, oxidative stress and/or apoptosis.
Similar articles
-
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.Behav Pharmacol. 2010 May;21(3):194-205. doi: 10.1097/FBP.0b013e32833a5c81. Behav Pharmacol. 2010. PMID: 20440202
-
CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.J Pharmacol Exp Ther. 1999 Feb;288(2):421-7. J Pharmacol Exp Ther. 1999. PMID: 9918541
-
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.Neuroscience. 2006 Jun 19;140(1):67-76. doi: 10.1016/j.neuroscience.2006.02.007. Epub 2006 Mar 14. Neuroscience. 2006. PMID: 16533572
-
Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.Med Sci Monit. 2005 Jan;11(1):RA17-23. Med Sci Monit. 2005. PMID: 15614202 Review.
-
[Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].Arch Neurobiol (Madr). 1992 Jul-Aug;55(4):175-82. Arch Neurobiol (Madr). 1992. PMID: 1417423 Review. Spanish.
Cited by
-
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors.Biol Psychiatry. 2011 Apr 1;69(7):633-41. doi: 10.1016/j.biopsych.2010.07.009. Biol Psychiatry. 2011. PMID: 20801430 Free PMC article.
-
The Potential Role of PPARs in the Fetal Origins of Adult Disease.Cells. 2022 Nov 2;11(21):3474. doi: 10.3390/cells11213474. Cells. 2022. PMID: 36359869 Free PMC article. Review.
-
Major Alterations of Phosphatidylcholine and Lysophosphotidylcholine Lipids in the Substantia Nigra Using an Early Stage Model of Parkinson's Disease.Int J Mol Sci. 2015 Aug 12;16(8):18865-77. doi: 10.3390/ijms160818865. Int J Mol Sci. 2015. PMID: 26274953 Free PMC article.
-
Prospects of statins in Parkinson disease.Neuroscientist. 2011 Jun;17(3):244-55. doi: 10.1177/1073858410385006. Epub 2011 Jan 20. Neuroscientist. 2011. PMID: 21252380 Free PMC article. Review.
-
Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARα agonist fenofibrate in a rat model.Psychopharmacology (Berl). 2011 Mar;214(1):285-96. doi: 10.1007/s00213-010-1960-2. Epub 2010 Jul 27. Psychopharmacology (Berl). 2011. PMID: 20661551
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous